(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.36%) $78.10
(0.36%) $2.22
(-0.16%) $2 320.50
(-0.30%) $27.46
(-0.02%) $988.20
(0.15%) $0.931
(0.39%) $10.94
(0.13%) $0.800
(0.03%) $91.47
0.52% $ 15.53
@ $15.84
Wydano: 14 vas. 2024 @ 22:17
Zwrot: -1.96%
Poprzedni sygnał: vas. 14 - 20:26
Poprzedni sygnał:
Zwrot: 0.54 %
Live Chart Being Loaded With Signals
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA...
Stats | |
---|---|
Dzisiejszy wolumen | 385 342 |
Średni wolumen | 713 250 |
Kapitalizacja rynkowa | 970.91M |
EPS | $0 ( 2024-02-27 ) |
Następna data zysków | ( $0.170 ) 2024-05-14 |
Last Dividend | $0.250 ( 2015-09-08 ) |
Next Dividend | $0 ( N/A ) |
P/E | 7.06 |
ATR14 | $0.00600 (0.04%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-29 | Small Derek A | Sell | 1 206 | Restricted Stock Units |
2024-04-29 | Small Derek A | Sell | 833 | Stock Options |
2024-03-05 | Basso Stephen | Buy | 25 899 | Non-statutory Stock Option |
2024-03-05 | Basso Stephen | Buy | 12 096 | Common Stock |
2024-03-05 | Ronsheim Matthew | Buy | 27 338 | Non-statutory Stock Option |
INSIDER POWER |
---|
89.34 |
Last 96 transactions |
Buy: 2 118 652 | Sell: 32 095 513 |
Wolumen Korelacja
Innoviva Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ONEM | 0.92 |
ESSA | 0.92 |
NAKD | 0.911 |
AADI | 0.909 |
AROW | 0.908 |
DSWL | 0.906 |
AZTA | 0.905 |
BSRR | 0.904 |
UK | 0.902 |
SRDX | 0.897 |
10 Najbardziej negatywne korelacje | |
---|---|
NEO | -0.927 |
TMDX | -0.919 |
MORF | -0.916 |
ACVA | -0.913 |
SGTX | -0.911 |
SJ | -0.909 |
MHUA | -0.909 |
MYNA | -0.907 |
RMRM | -0.907 |
MLTX | -0.904 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Innoviva Inc Korelacja - Waluta/Towar
Innoviva Inc Finanse
Annual | 2023 |
Przychody: | $324.26M |
Zysk brutto: | $245.92M (75.84 %) |
EPS: | $-1.910 |
FY | 2023 |
Przychody: | $324.26M |
Zysk brutto: | $245.92M (75.84 %) |
EPS: | $-1.910 |
FY | 2022 |
Przychody: | $331.34M |
Zysk brutto: | $317.55M (95.84 %) |
EPS: | $-1.080 |
FY | 2021 |
Przychody: | $391.87M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $2.62 |
Financial Reports:
No articles found.
Innoviva Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.250 | 2014-08-26 |
Last Dividend | $0.250 | 2015-09-08 |
Next Dividend | $0 | N/A |
Payout Date | 2015-09-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $1.250 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.77 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 3.68 | |
Div. Directional Score | 7.39 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $0.500 | 1.84% |
2015 | $0.750 | 5.65% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.573 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.145 | 1.200 | 5.18 | 6.22 | [0 - 0.3] |
returnOnEquityTTM | 0.297 | 1.500 | 7.81 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.03 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.28 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 5.07 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.360 | -1.500 | 4.00 | -6.00 | [0 - 0.6] |
interestCoverageTTM | 9.70 | 1.000 | 7.52 | 7.52 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.21 | 2.00 | 9.26 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.21 | 2.00 | 8.90 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.663 | -1.500 | 7.35 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.832 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.592 | 1.000 | 0.162 | 0.162 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.315 | 1.000 | 9.36 | 9.36 | [0.2 - 2] |
assetTurnoverTTM | 0.252 | 0.800 | -1.650 | -1.320 | [0.5 - 2] |
Total Score | 11.10 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 5.48 | 1.000 | 9.55 | 0 | [1 - 100] |
returnOnEquityTTM | 0.297 | 2.50 | 8.59 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.21 | 2.00 | 9.26 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.21 | 2.00 | 9.26 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.103 | 1.500 | -2.64 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.449 | 1.000 | 1.265 | 0 | [0.1 - 0.5] |
Total Score | 3.68 |
Innoviva Inc
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej